Divi’s Laboratories

Divi's Labs stock tanks 12% on big miss in Q3; near-term trend 'bearish'

Analysts' average price target of Rs 3,862, however, indicates significant upside. The near-term trend remains bearish

Divi's Lab sinks 13%, hits 29-mth low as Q3 profit falls more than expected

In Q3FY23, Divi's Lab reported a 66 per cent year-on-year decline in its consolidated net profit at Rs 306.80 crore, on higher than expected in fall in revenue

Measuring worth: Front-row seats to high return-on-equity stocks

A portfolio of richly valued RoE stocks is expected to outperform the broader market over the longer term.

Divi's Lab Q2 net profit dips 18% to Rs 494 cr, revenue down to Rs 1,854 cr

Divi's Laboratories on Monday said its consolidated net profit declined by 18 per cent to Rs 494 crore in the second quarter of the current financial year. The drug firm had reported a net profit of Rs 606 crore in the July-September period of last fiscal. Revenue from operations declined to Rs 1,854 crore in the September quarter as against Rs 1,987 crore in the year-ago period. Shares of the company on Monday ended 8.63 per cent at Rs 3,422 apiece on the BSE.

Pharma firm Divi's FY23 growth shaped by high base, near-term weakness

Brokerages give add, accumulate or buy ratings given the company's growth and track record

Top executives in Indian companies made 184 times their employees in FY21

The analysis is based on a common sample of 76 companies from the Nifty 100 index

Multiple near-term concerns trigger Divi's Laboratories' headache

Pfizer's oral Covid drug, weak sales of generics, and valuations may cap upsides

Pfizer's oral Covid-19 drug may hit revenues of Divi's Laboratories

Supply of Molnupiravir to Merck was a key near-term trigger for the stock

Lack of valuation comfort may limit gains in Divi's Laboratories stock

Revenue growth prospects, however, remain strong driven by multiple factors

Strong growth prospects drive Divi's Laboratories earnings upgrades

Ongoing capacity additions, market share gains, and new launches are key triggers

Divi's Laboratories shares jump 4% after robust Jan quarter earnings

Shares of Divi's Laboratories on Monday gained 4 per cent after the company reported a 29.30 per cent rise in its consolidated net profit for the quarter ended March 31, 2021

Divi's Labs Q4 net profit jumps 29% at Rs 502 crore on robust sales

Drug firm Divi's Laboratories on Saturday reported a 29.30 percent rise in its consolidated net profit to Rs 502.02 crore for the quarter ended March 31, 2021, on account of robust sales

Divi's Lab Q4 net profit rises 25% to Rs 488 cr, aided by low base

However, the company's earnings showed strong traction in 2020-21 due to a surge in demand for bulk drugs caused by the pandemic

Project pipeline, ongoing expansion offer revenue visibility for Divi's

Divi's Laboratories Q3 results: While top line growth was strong, margin performance stood out in the December quarter

IT, pharma firms emerge Samvat 2076 winners; Infy, Divi's Lab top gainers

On the other hand, PSU stocks and banks have been laggards - with ONGC, Indian Oil, IndusInd Bank, and Coal India delivering the worst returns.

This India-focused fund beating 98% of peers targets crisis winners

According to the fund's profile, its top holding as of July 31 was drugmaker Divi's Laboratories Ltd., which has gained more than 70% in 2020

Divi's Laboratories, SBI Life Insurance shares gain on Nifty inclusion

Shares of Zee Entertainment Enterprises fell 3.7 per cent and that of Bharti Infratel ended flat. The two companies will be removed from the bluechip index

Divi's, SBI Life to see combined inflows of Rs 1,400 cr on Nifty inclusion

Over Rs 650-cr selling in Zee, Infratel

Divi's Labs: APIs, custom synthesis, ongoing capex plan to support growth

The near term upside, however, is limited given the sharp stock price run up

Nifty rejig announcement: Divi's Lab hits all-time high, SBI Life gains 4%

For the quarter ended June 2020, Divi's Lab reported a net profit of Rs 492.06 crore on account of robust sales.